Chicago, IL, United States

Vancive Medical Technologies

vancive.averydennison.com/
Chicago, IL, United States
SEARCH FILTERS
Time filter
Source Type

News Article | May 22, 2017
Site: www.businesswire.com

GLENDALE, Calif.--(BUSINESS WIRE)--Avery Dennison Corporation (NYSE:AVY) announced today that it has acquired Finesse Medical Ltd., an innovator in the development and manufacture of healthcare products used in the management of wound care and skin conditions. Headquartered in Longford, Ireland, Finesse Medical specializes in the development and application of advanced technologies in wound care and skin treatment, including skin barrier films and protection creams, and silicone and polyurethane foam wound dressings. With revenue over the last year of approximately €15 million, the company is a key supplier to global healthcare-product OEMs and also provides contract manufacturing and product development services. “Finesse Medical is a top quality manufacturer with a strong track record for developing and commercializing effective, high-value products in the medical sector,” said Mitch Butier, Avery Dennison’s president and CEO. “This acquisition will accelerate the achievement of our long-term strategic and financial goals for our industrial and healthcare materials segment.” “Finesse Medical is a great strategic fit with Vancive Medical Technologies,” added Mike Johansen, vice president and general manager of Avery Dennison’s Industrial and Healthcare Materials group. “Its innovative portfolio of silicone gels and polyurethane foam dressings builds on and complements our existing products in wound care. And its converting and packaging capabilities will enable us to offer expanded manufacturing services to our customers.” “Uniting our two healthcare businesses is a strategic win for both organizations and our global customer base,” said Martin Dowd, director, marketing & business development, at Finesse Medical. “Our companies share a strong commitment to quality, service and innovation. Avery Dennison brings important new strengths to our business, including key relationships in the U.S. healthcare industry, new global sales and distribution channels for our products, and coating and roll manufacturing expertise that deepens our service offerings.” Avery Dennison (NYSE: AVY) is a global leader in pressure-sensitive and functional materials and labeling solutions for the retail apparel market. The company’s applications and technologies are an integral part of products used in every major industry. With operations in more than 50 countries and more than 25,000 employees worldwide, Avery Dennison serves customers in the consumer packaging, graphical display, logistics, apparel, industrial and healthcare industries. Headquartered in Glendale, California, the company reported sales of $6.1 billion in 2016. Learn more at www.averydennison.com.


FERNDALE, Mich.--(BUSINESS WIRE)--Vancive Medical Technologies™, an Avery Dennison (NYSE:AVY) business, and Eloquest Healthcare®, Inc. have partnered to develop an innovative post-operative dressing that contains an antimicrobial agent called chlorhexidine gluconate (CHG). The antimicrobial properties of CHG inhibit microbial growth within the dressing. CHG is extremely difficult to incorporate in an absorbent adhesive dressing, making the development of the BeneHold™ CHG platform a significant technical accomplishment for Vancive. The Eloquest Healthcare ReliaTect™ Post-Op Dressings with CHG are the first to combine CHG in an absorbent, transparent and waterproof design. “ReliaTect post-operative dressings are a natural fit for our BeneHold CHG platform, and the needs of patients and clinicians,” said Kirsten Newquist, general manager for Vancive Medical Technologies. “We look forward to further expanding our CHG technology to many more applications.” ReliaTect is available in small and large sizes with a transparent window for surgical site visualization, and a nonwoven border that facilitates dressing application and provides additional securement during wear. The dressings comfortably adhere to the skin, absorb fluids and protect the site from external contaminants. “Chlorhexidine Gluconate (CHG) is a trusted antiseptic in pre-operative site treatment,” said Tim O’Halla, president and CEO for Eloquest Healthcare. “By combining its antimicrobial properties with the sustained transparency and absorbency of our ReliaTect Post-Op Dressings, we are bringing to market a truly patient friendly post-operative dressing with proven antimicrobial activity.” ReliaTect Post-Op Dressings with CHG are now commercially available from Eloquest Healthcare in the United States. The device received 510(k) clearance from the FDA in March and is now available nationwide. Eloquest Healthcare is the exclusive distributor of the dressings in the United States and Canada. To learn more or request a sample visit, www.ReliaTectPostOp.com or contact Eloquest Healthcare customer service at 1-877-433-7626. Eloquest Healthcare, Inc. is a wholly owned subsidiary of Ferndale Pharma Group, Inc. that is focused specifically on serving hospitals, their healthcare practitioners, and patients. Eloquest Healthcare helps deliver safer, more compassionate care by providing intuitive, cost-effective solutions that complement treatment protocols. More information can be found at www.eloquesthealthcare.com. Vancive Medical Technologies is a medical technology company with more than three decades of expertise in adhesive chemistries and material technologies for medical applications using pressure sensitive adhesives. The company's applications and technologies are an integral part of products that are in daily use in medical facilities throughout the world. Through long-term relationships with original equipment manufacturers, industry-specific converters and leading universities, Vancive Medical Technologies continually finds new ways to develop products that can improve patient care. Vancive Medical Technologies is an Avery Dennison business headquartered in Chicago, Illinois. To learn more about Vancive Medical Technologies, visit www.vancive.averydennison.com. Avery Dennison (NYSE:AVY) is a global leader in pressure-sensitive and functional materials and labeling solutions for the retail apparel market. The company’s applications and technologies are an integral part of products used in every major industry. With operations in more than 50 countries and more than 25,000 employees worldwide, Avery Dennison serves customers in the consumer packaging, graphical display, logistics, apparel, industrial and healthcare industries. Headquartered in Glendale, California, the company reported sales of $6.1 billion in 2016. Learn more at www.averydennison.com.


Bertram T.A.,RegeMedTX | Johnson P.C.,Vancive Medical Technologies | Tawil B.J.,University of California at Los Angeles | Van Dyke M.,Virginia Polytechnic Institute and State University | Hellman K.B.,Hellman Group
Tissue Engineering - Part A | Year: 2015

TERMIS-AM Industry Committee (TERMIS-AM/IC), in collaboration with the TERMIS-Europe (EU)/IC, conducted a symposium involving the European Medicines Agency and the U.S. Food and Drug Administration (FDA) toward building an understanding of the rational basis for regulatory decision-making and providing a framework for decisions made during the evaluation of safety and efficacy of TE/RM technologies. This symposium was held in August 2012 during the TERMIS-WC in Vienna, Austria. Emerging from this international initiative by the European Union and the United States, representatives from the respective agencies demonstrated that there are ongoing interagency efforts for developing common national practices toward harmonization of regulatory requirements for the TE/RM products. To extend a broad-based understanding of the role of science in regulatory decision-making, TERMIS-AM/IC, in cooperation with the FDA, organized a symposium at the 2014 TERMIS-AM Annual Meeting, which was held in Washington, DC. This event provided insights from leaders in the FDA and TERMIS on the current status of regulatory approaches for the approved TE/RM products, the use of science in making regulatory decisions, and TE/RM technologies that are in the development pipeline to address unmet medical needs. A far-ranging discussion with FDA representatives, industrialists, physicians, regenerative medicine biologists, and tissue engineers considered the gaps in today's scientific and regulatory understanding of TE/RM technologies. The identified gaps represent significant opportunities to advance TE/RM technologies toward commercialization. © Mary Ann Liebert, Inc. 2015.


PubMed | 5 The Hellman Group, 1 RegeMedTX, Virginia Polytechnic Institute and State University, University of California at Los Angeles and Vancive Medical Technologies
Type: Journal Article | Journal: Tissue engineering. Part A | Year: 2015

TERMIS-AM Industry Committee (TERMIS-AM/IC), in collaboration with the TERMIS-Europe (EU)/IC, conducted a symposium involving the European Medicines Agency and the U.S. Food and Drug Administration (FDA) toward building an understanding of the rational basis for regulatory decision-making and providing a framework for decisions made during the evaluation of safety and efficacy of TE/RM technologies. This symposium was held in August 2012 during the TERMIS-WC in Vienna, Austria. Emerging from this international initiative by the European Union and the United States, representatives from the respective agencies demonstrated that there are ongoing interagency efforts for developing common national practices toward harmonization of regulatory requirements for the TE/RM products. To extend a broad-based understanding of the role of science in regulatory decision-making, TERMIS-AM/IC, in cooperation with the FDA, organized a symposium at the 2014 TERMIS-AM Annual Meeting, which was held in Washington, DC. This event provided insights from leaders in the FDA and TERMIS on the current status of regulatory approaches for the approved TE/RM products, the use of science in making regulatory decisions, and TE/RM technologies that are in the development pipeline to address unmet medical needs. A far-ranging discussion with FDA representatives, industrialists, physicians, regenerative medicine biologists, and tissue engineers considered the gaps in todays scientific and regulatory understanding of TE/RM technologies. The identified gaps represent significant opportunities to advance TE/RM technologies toward commercialization.


News Article | December 5, 2016
Site: www.newsmaker.com.au

Wearable Electronics are minute electronics devices worn by the consumer which enable wireless networking and mobile computing. The word “wearable technology” refers to any electronic device or product which can be worn by a person to add computing in his action or work and utilize technology to benefit advanced features and characteristics. Wearable electronics may consist of glasses, jewelry, headgear, belts, arm wear, wrist wear, leg wear, footwear, skin patches, and e-textiles. In recent years, there has been lots of research and development going in the field of wearable electronics attributed to their popularity and wide acceptance in global market. North America is the largest market for wearable electronics followed by Europe and Asia Pacific. In the last few years, North America has been witnessing the fastest growth rate; however Asia Pacific region is expected to take over as the fastest growing market in upcoming years. Some of the major drivers of the industry include increasing demand of consumers towards communication, networking, positioning and recognition technologies in compact and portable forms, developments in material science, augmented reality and chip evolution and low power inter device connectivity (Bluetooth 4.0, infra red and NFC). Some of the key challenges for the industry are thermal consideration, negative effect of radiation on human health, and device protection. With the growth of sensors, particularly in the health and medical space, the potential uses of wearable computing technologies are quite extensive. Wearable electronics are expected to increase their adoption levels in different sectors such as health and fitness, gaming, fashion, mobile money, education and transportation. Rising average life expectancy, baby boomers population and larger proportion of patients requiring long term treatment are some of the key drivers in healthcare and medicine segment whereas demands from professional athletes, recreational fitness consumers, and corporate wellness programs are propelling the market of wearable technology in fitness and wellness sector. The ongoing military up gradation programs around the globe such as, the U.S.’s ‘Future Force Warrior (FFW)’, Australia’s ‘Project Wundurra’, Israel’s ‘Integrated Advanced Soldier (IAS)’, and the U.K.’s ‘Future Infantry Soldier Technology’ are expected to increase the overall market share of wearable electronics market in military and defense. Request for Sample Report and Table of content @: http://www.persistencemarketresearch.com/toc/3035 Some of the key players in the wearable electronics market include Adidas AG, Recon Instruments, Inc., Fibretronic Ltd., Jawbone, Inc., Fitbit, Inc., Nike, Inc. (U.S.), Olympus Corporation, and Weartech s.l, Vuzix Corporation , Google, Inc., Apple, Inc.,By-Wire.Net, Imprint Energy, Inc, Jawbone, Inc., O’neill Wetsuits LIC, Plastic Logic Ltd., Texas Instruments, Inc., Zoog Technologies, Inc., Weartech S.L, Shimmer Research, Inc., Vancive Medical Technologies, Infineon Technologies Ag, Glassup SRL, Eurotech S.P.A, and AT&T, Inc.


Research and Markets has announced the addition of the "Global Low Trauma/Skin Friendly Adhesives Market Outlook: 2014-2021" report to their offering. The global market for low trauma/skin friendly adhesives will increase at a CAGR of 7.6% from 2016 to 2021 to $160.56 million in 2021, driven by growing application areas, increasing healthcare outsourcing trend, increasing home healthcare demand, and growing wound care, wearable medical devices, and drug delivery devices market. However, reimbursement challenges and stringent and complex regulatory process hinders the growth of the global low trauma/ skin friendly adhesives market to some extent. The non-silicone adhesives market is expected to witness significant growth in the next few years owing to their low cost and ability to provide better moisture management, patient comfort, and extended wear times. This study analyzes the global low trauma/skin friendly adhesives industry. It presents market size for 2014, 2015, and 2016, with a forecast till 2021 by chemistry/technology (Silicone based, acrylics, and others), application (wound care, medical devices, drug delivery devices, and others), and geography (North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. The study also considers environment factors, details industry structure, analyzes market dynamics, evaluates market share of various companies, and profiles 12 industry players, including 3M Company, Scapa Healthcare, Adhesives Research Inc., Vancive Medical Technologies, Tesa Group, Nitto Denko Corporation, and Lohmann Group For more information about this report visit http://www.researchandmarkets.com/research/5t7gqs/global_low


News Article | December 19, 2016
Site: www.businesswire.com

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Low Trauma/Skin Friendly Adhesives Market Outlook: 2014-2021" report to their offering. The global market for low trauma/skin friendly adhesives will increase at a CAGR of 7.6% from 2016 to 2021 to $160.56 million in 2021, driven by growing application areas, increasing healthcare outsourcing trend, increasing home healthcare demand, and growing wound care, wearable medical devices, and drug delivery devices market. However, reimbursement challenges and stringent and complex regulatory process hinders the growth of the global low trauma/skin friendly adhesives market to some extent. The non-silicone adhesives market is expected to witness significant growth in the next few years owing to their low cost and ability to provide better moisture management, patient comfort, and extended wear times. This study analyzes the global low trauma/skin friendly adhesives industry. It presents market size for 2014, 2015, and 2016, with a forecast till 2021 by chemistry/technology (Silicone based, acrylics, and others), application (wound care, medical devices, drug delivery devices, and others), and geography (North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa). The study also considers environment factors, details industry structure, analyzes market dynamics, evaluates market share of various companies, and profiles 12 industry players, including 3M Company, Scapa Healthcare, Adhesives Research Inc., Vancive Medical Technologies, Tesa Group, Nitto Denko Corporation, and Lohmann Group For more information about this report visit http://www.researchandmarkets.com/research/g4z7x8/global_low


Stephen-Haynes J.,City University London | Stephen-Haynes J.,Worcestershire Health and Care NHS Trust | Callaghan R.,Worcestershire Health and Care NHS Trust | Wibaux A.,Vancive Medical Technologies | And 2 more authors.
Journal of Wound Care | Year: 2014

Objective: This article assesses the use of BeneHold Thin Absorbent Skin Adhesive (TASA) wound dressings in a large UK primary care organisation. These wound dressings are thin (0.12mm), breathable, transparent, and are able to absorb and retain wound exudate. This non-comparative evaluation was undertaken to explore the clinical advantages this differentiated combination of physical properties offered. Method: The dressings are CE-marked medical devices, and were used on patients with acute and chronic wounds that were assessed and classified as light to moderately exuding. Clinical performance was evaluated with respect to the dressing's ease of use (application and removal, conformability, mould-ability, rolling and edge-lift), debridement, protection of the peri-wound, wear time, fluid handling, wound bed residue, visibility of the wound, and clinical acceptability. The evaluating clinicians used an agreed audit tool to collect data from case reports to document the progression of wounds of various aetiologies, including chronic and acute, for a maximum period of four weeks. Qualitative feedback on dressing performance was also collected at the evaluation's end, both from the clinicians' and patients' perspectives Results: Some 15 patients were assessed. The wear time was up to seven days in many cases, and on average was 3.9 days longer than their previous dressings. Clinicians perceived that wounds progressed toward healing in all but two cases, where the wounds remained unchanged. Out of five cases where wounds presented with necrosis, all underwent significant autolytic debridement underneath the new dressings. Transparency was a noted benefit from both the clinicians' and patients' perspectives because it enabled continuous monitoring of the full wound bed and peri-wound skin without the need to disrupt the dressing. Conclusion: The dressing was well-received by both clinicians and patients in all fifteen cases. The thin absorbent skin adhesive dressing was found to be a promising new technology that could offer significant advantages to improve the quality, cost, and convenience of wound care. Further work is underway to validate these findings in larger and more homogeneous patient groups. © 2014 MA HEALTHCARE LTD


PubMed | Vancive Medical Technologies and Gibraltar Laboratories Inc.
Type: Journal Article | Journal: PloS one | Year: 2015

Covering insertion sites with chlorhexidine impregnated dressings has been proven to be clinically effective in reducing catheter related blood stream infections (CR-BSI). Two chlorhexidine gluconate (CHG)-impregnated dressings are commercially available, a polyurethane foam disk and a film dressing containing a chlorhexidine gluconate-impregnated gel pad. While both have demonstrated efficacy in clinical settings, the major drawback of high cost and impaired IV insertion site visibility limits their usage. A new, simple film dressing containing CHG within its adhesive layer is now available. The objective of this study was to test the in vitro antimicrobial efficacy of the new dressing in comparison to the CHG-impregnated gel dressing.Quantitative aliquots of suspensions (concentration of 1.0x106 to 5.0x106 cfu/sample) of clinically relevant challenge organisms (Staphylococcus species, gram-negative bacilli, Candida albicans) were incubated in contact with the new CHG-containing film dressing, a placebo version of the same (negative control) and the commercially available CHG-impregnated gel dressing (positive control). Serial dilutions of the surviving organisms were quantified using the pour plate after 1, 3, 5, and 7 days of incubation in order to calculate an antimicrobial log10 reduction for each organism/dressing combination at each point in time.The new CHG-containing film dressing delivered greater than 5.0 log10 reduction throughout the 7 days on all aerobic gram-negative bacilli and Staphylococcus species tested. As of day 1 the CHG-containing film dressing provided greater than 5.0 log10 reduction on Candida albicans. There were no statistically significant differences in the log10 reduction between the two dressings tested.The new CHG-containing film dressing was found to be as effective as the chlorhexidine gluconate-impregnated gel dressing on clinically relevant microbes.


Carty N.,Vancive Medical Technologies | Wibaux A.,Vancive Medical Technologies | Ward C.,Vancive Medical Technologies | Paulson D.S.,BioScience Laboratories Inc. | Johnson P.,Vancive Medical Technologies
Journal of Antimicrobial Chemotherapy | Year: 2014

Objectives: To evaluate the antimicrobial activity of a new, transparent composite film dressing, whose adhesive contains chlorhexidine gluconate (CHG), against the native microflora present on human skin. Methods: CHG-containing adhesive film dressings and non-antimicrobial control film dressings were applied to the skin on the backs of healthy human volunteers without antiseptic preparation. Dressingswere removed 1, 4 or 7 days after application. The bacterial populations underneath were measured by quantitative cultures (cylinderscrub technique) and compared with one another as a function of time. Results: The mean baseline microflora recovery was 3.24 log10 cfu/cm2. The mean log reductions from baseline measured from underneath the CHG-containing dressings were 0.87, 0.78 and 1.30 log10 cfu/cm2 on days 1, 4 and 7, respectively, compared with log reductions of 0.67, 20.87 and 21.29 log10 cfu/cm2 from underneath the control film dressings. There was no significant difference between the log reductions of the two treatments on day 1, but on days 4 and 7 the log reduction associated with the CHG adhesive was significantly higher than that associated with the control adhesive. Conclusions: The adhesive containing CHG was associated with a sustained antimicrobial effect that was not present in the control. Incorporating the antimicrobial into the adhesive layer confers upon it bactericidal properties in marked contrast to the non-antimicrobial adhesive, which contributed to bacterial proliferation when the wear time was ≥4 days. © The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.

Loading Vancive Medical Technologies collaborators
Loading Vancive Medical Technologies collaborators